Antiangiogenic activity of trabectedin in myxoid liposarcoma: Involvement of host TIMP-1 and TIMP-2 and tumor thrombospondin-1

International Journal of Cancer

Volumn 136, Issue 3, 2015, Pages 721-729

  Dossi, Romina ^a   Frapolli, Roberta ^a   Di Giandomenico, Silvana ^a   Paracchini, Lara ^a   Bozzi, Fabio ^b   Brich, Silvia ^b   Castiglioni, Vittoria ^c   Borsotti, Patrizia ^a   Belotti, Dorina ^a   Uboldi, Sarah ^a   Sanfilippo, Roberta ^b   Erba, Eugenio ^a   Giavazzi, Raffaella ^a   Marchini, Sergio ^a   Pilotti, Silvana ^b   D'Incalci, Maurizio ^a   Taraboletti, Giulia ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Angiogenesis; Myxoid liposarcoma; Thrombospondin 1; TIMP; Trabectedin

Indexed keywords

THROMBOSPONDIN 1; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRABECTEDIN; 1,3 DIOXOLANE DERIVATIVE; ANGIOGENESIS INHIBITOR; CCAAT ENHANCER BINDING PROTEIN BETA; TETRAHYDROISOQUINOLINE DERIVATIVE; TIMP1 PROTEIN, HUMAN; TIMP2 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CELL DIFFERENTIATION; CHROMATIN IMMUNOPRECIPITATION; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MYXOSARCOMA; NONHUMAN; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; C57BL MOUSE; CELL CULTURE; DRUG EFFECTS; ENDOTHELIUM CELL; LIPOSARCOMA, MYXOID; METABOLISM; PHYSIOLOGY; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CCAAT-ENHANCER-BINDING PROTEIN-BETA; CELLS, CULTURED; DIOXOLES; ENDOTHELIAL CELLS; FEMALE; HUMANS; LIPOSARCOMA, MYXOID; MICE; MICE, INBRED C57BL; TETRAHYDROISOQUINOLINES; THROMBOSPONDIN 1; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 84911007522     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29023     Document Type: Article

References (45)

1. D'Incalci M, Galmarini CM. A review of trabectedin (ET-743): a unique mechanism of action. Mol Cancer Ther 2010;9:2157-63.
2. Minuzzo M, Marchini S, Broggini M, et al. Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc Natl Acad Sci USA 2000;97:6780-4.
3. Allavena P, Signorelli M, Chieppa M, et al. Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Res 2005;65: 2964-71.
4. Germano G, Frapolli R, Belgiovine C, et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell 2013;23: 249-62.
5. Germano G, Frapolli R, Simone M, et al. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res 2010;70:2235-44.
6. Grosso F, Jones RL, Demetri GD, et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 2007;8:595-602.
7. Panagopoulos I, Hoglund M, Mertens F, et al. Fusion of the EWS and CHOP genes in myxoid liposarcoma. Oncogene 1996;12:489-94.
8. Taylor BS, Barretina J, Maki RG, et al. Advances in sarcoma genomics and new therapeutic targets. Nat Rev Cancer 2011;11:541-57.
9. Lowe CE, O'Rahilly S, Rochford JJ. Adipogenesis at a glance. J Cell Sci 2011;124:2681-6.
10. Cristancho AG, Lazar MA. Forming functional fat: a growing understanding of adipocyte differentiation. Nat Rev Mol Cell Biol 2011; 12:722-34.
11. Forni C, Minuzzo M, Virdis E, et al. Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol Cancer Ther 2009;8:449-57.
12. Di Giandomenico S, Frapolli R, Bello E, et al. Mode of action of trabectedin in myxoid liposarcomas. Oncogene, in press. doi: 10.1038/onc.2013.462.
13. Aman P, Ron D, Mandahl N, et al. Rearrangement of the transcription factor gene CHOP in myxoid liposarcomas with t(12;16)(q13;p11). Genes Chromosomes Cancer 1992;5:278-85.
14. Uboldi S, Bernasconi S, Romano M, et al. Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents. Int J Cancer 2012; 131:59-69.
15. Frapolli R, Tamborini E, Virdis E, et al. Novel models of myxoid liposarcoma xenografts mimicking the biological and pharmacologic features of human tumors. Clin Cancer Res 2010;16:4958-67.
16. Kruczynski A, Poli M, Dossi R, et al. Anti-angiogenic, vascular-disrupting and anti-metastatic activities of vinflunine, the latest vinca alkaloid in clinical development. Eur J Cancer 2006;42:2821-32.
17. Mentzel T, Brown LF, Dvorak HF, et al. The association between tumour progression and vascularity in myxofibrosarcoma and myxoid/round cell liposarcoma. Virchows Arch 2001;438:13-22.
18. Almog N, Henke V, Flores L, et al. Prolonged dormancy of human liposarcoma is associated with impaired tumor angiogenesis. FASEB J 2006; 20:947-9.
19. Taraboletti G, Benelli R, Borsotti P, et al. Thrombospondin-1 inhibits Kaposi's sarcoma (KS) cell and HIV-1 Tat-induced angiogenesis and is poorly expressed in KS lesions. J Pathol 1999;188: 76-81.
20. Potikyan G, Savene RO, Gaulden JM, et al. EWS/ FLI1 regulates tumor angiogenesis in Ewing's sarcoma via suppression of thrombospondins. Cancer Res 2007;67:6675-84.
21. Basu SK, Malik R, Huggins CJ, et al. 3'UTR elements inhibit Ras-induced C/EBPbeta posttranslational activation and senescence in tumour cells. EMBO J 2011;30:3714-28.
22. Tigges U, Hyer EG, Scharf J, et al. FGF2-dependent neovascularization of subcutaneous Matrigel plugs is initiated by bone marrow-derived pericytes and macrophages. Development 2008;135: 523-32.
23. Stetler-Stevenson WG, Seo DW. TIMP-2: an endogenous inhibitor of angiogenesis. Trends Mol Med 2005;11:97-103.
24. Seo DW, Li H, Guedez L, et al. TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism. Cell 2003;114:171-80.
25. Fernandez CA, Roy R, Lee S, et al. The antiangiogenic peptide, loop 6, binds insulin-like growth factor-1 receptor. J Biol Chem 2010;285: 41886-95.
26. Lawler PR, Lawler J. Molecular basis for the regulation of angiogenesis by thrombospondin-1 and 22. Cold Spring Harb Perspect Med 2012;2: a006627.
27. Margosio B, Rusnati M, Bonezzi K, et al. Fibroblast growth factor-2 binding to the thrombospondin-1 type III repeats, a novel antiangiogenic domain. Int J Biochem Cell Biol 2008; 40:700-9.
28. Margosio B, Marchetti D, Vergani V, et al. Thrombospondin 1 as a scavenger for matrixassociated fibroblast growth factor 2. Blood 2003; 102:4399-406.
29. Taraboletti G, Belotti D, Borsotti P, et al. The 140-kilodalton antiangiogenic fragment of thrombospondin-1 binds to basic fibroblast growth factor. Cell Growth Differ 1997;8:471-9.
30. Taraboletti G, Rusnati M, Ragona L, et al. Targeting tumor angiogenesis with TSP-1-based compounds: rational design of antiangiogenic mimetics of endogenous inhibitors. Oncotarget 2010;1:662-73.
31. Almog N, Ma L, Raychowdhury R, et al. Transcriptional switch of dormant tumors to fastgrowing angiogenic phenotype. Cancer Res 2009; 69:836-44.
32. Christiaens V, Lijnen HR. Angiogenesis and development of adipose tissue. Mol Cell Endocrinol 2010;318:2-9.
33. Chen X, Cushman SW, Pannell LK, et al. Quantitative proteomic analysis of the secretory proteins from rat adipose cells using a 2D liquid chromatography-MS/MS approach. J Proteome Res 2005; 4:570-7.
34. Alvarez-Llamas G, Szalowska E, de Vries MP, Weening D, Landman K, Hoek A, Wolffenbuttel BH, Roelofsen H, Vonk RJ. Characterization of the human visceral adipose tissue secretome. Mol Cell Proteomics 2007;6:589-600.
35. Varma V, Yao-Borengasser A, Bodles AM, et al. Thrombospondin-1 is an adipokine associated with obesity, adipose inflammation, and insulin resistance. Diabetes 2008;57:432-9.
36. Hocking SL, Wu LE, Guilhaus M, et al. Intrinsic depot-specific differences in the secretome of adipose tissue, preadipocytes, and adipose tissuederived microvascular endothelial cells. Diabetes 2010;59:3008-16.
37. Voros G, Maquoi E, Demeulemeester D, et al. Modulation of angiogenesis during adipose tissue development in murine models of obesity. Endocrinology 2005;146:4545-54.
38. Inuzuka H, Nanbu-Wakao R, Masuho Y, et al. Differential regulation of immediate early gene expression in preadipocyte cells through multiple signaling pathways. Biochem Biophys Res Commun 1999;265:664-8.
39. Shang CA, Thompson BJ, Teasdale R, et al. Genes induced by growth hormone in a model of adipogenic differentiation. Mol Cell Endocrinol 2002;189:213-9.
40. Burton GR, Nagarajan R, Peterson CA, et al. Microarray analysis of differentiation-specific gene expression during 3T3-L1 adipogenesis. Gene 2004;329:167-85.
41. Okuno M, Arimoto E, Nishizuka M, et al. Isolation of up-or down-regulated genes in PPARgamma-expressing NIH-3T3 cells during differentiation into adipocytes. FEBS Lett 2002; 519:108-12.
42. Adelmant G, Gilbert JD, Freytag SO. Human translocation liposarcoma-CCAAT/enhancer binding protein (C/EBP) homologous protein (TLS-CHOP) oncoprotein prevents adipocyte differentiation by directly interfering with C/EBPbeta function. J Biol Chem 1998;273: 15574-81.
43. Demetri GD, Fletcher CD, Mueller E, et al. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci USA 1999;96: 3951-6.
44. Charytonowicz E, Terry M, Coakley K, et al. PPARgamma agonists enhance ET-743-induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcoma. J Clin Invest 2012;122:886-98.
45. Huang H, Campbell SC, Bedford DF, et al. Peroxisome proliferator-activated receptor gamma ligands improve the antitumor efficacy of thrombospondin peptide ABT510. Mol Cancer Res 2004;2:541-50.